Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
In heavily treated chronic lymphocytic leukemia patients who have poor prognoses and few options, the BTK degrader, NX-5948, was responsive.
October 2024 CLL Bloodline: Over the course of a year of monthly meetings, The CLL Society Bloodline will teach the BASICS needed to understand CLL.
Idelalisib is used in combination with another medication (rituximab) only after the disease has relapsed or is no longer responding to other CLL and SLL treatments.
CLL Society awarded Dr. Jennifer Brown a research grant for her project testing the combination of venetoclax and obinutuzumab with roginolisib for CLL.
Clinician Resource Library: Medication Fact Sheets Click below on each of the medications to print copies on demand or to order copies in bulk that will be shipped to you free
Understanding the medication you are on, or those you and your healthcare provider are considering for your treatment plan is important in decision-making, managing expectations, and addressing concerns and side effects in order to maximize the benefits of therapy.
TG Therapeutics, after a decade of development, is withdrawing its application for the combination of ublituximab and UKONIQ (umbralisib) (combination referred to as U2) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
At the American Society of Hematology (ASH) 2021, Dr. Alan Skarbnick, Director of the CLL program at Novant Health Cancer Institute in Charlotte, NC, interviewed Dr. Constantine Tam, a hematologist at the Peter McCallum Cancer Center in Melbourne, Australia. They discussed the results of a phase 1 clinical trial testing the combination of three different drugs:
Targeted Therapies Most new “small molecules” can be taken by mouth. Many work by blocking pathways that the cancer cells have pirated and become addicted to such as signaling pathways. Examples
One click to our most popular content.
